EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

The ERK5 pathway in BRAFV600E melanoma cells plays a role in development of acquired resistance to dabrafenib but not vemurafenib

Anil Kumar Mondru, Beth Wilkinson, Mohammad A Aljasir, Ahmed Alrumayh, Georgia Greaves, Maxine Emmett, Saad Albohairi, Rowan Pritchard-Jones, Michael J Cross iD

FEBS Letters · 2024

DOI: 10.1002/1873-3468.14960 ↗

Kurz gefasst

Fachartikel in der Zeitschrift FEBS Letters, 2024. Verfasst von Anil Kumar Mondru und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology and Therapeutics, Institute of Systems, Molecular and Integrative Biology, University of Liverpool, UK. Hauptthemen laut MEDLINE: Oximes, Proto-Oncogene Proteins B-raf, Melanoma, Imidazoles. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: North West Cancer Research, Skin Cancer Research Fund, Wellcome Trust Institutional Strategic Support Fund.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Malignant melanoma, an aggressive skin cancer with a poor prognosis, frequently features BRAFV600E mutation resulting in activation of the MAPK pathway and melanocyte proliferation and survival. BRAFV600E inhibitors like vemurafenib and dabrafenib have enhanced patient survival, yet drug resistance remains a significant challenge. We investigated the role of the ERK5 pathway in BRAFV600E melanoma cells and cells with acquired resistance to PLX4720 (vemurafenib) and dabrafenib. In BRAFV600E melanoma, ERK5 inhibition minimally affected viability compared to ERK1/2 inhibition. In vemurafenib‐resistant cells, ERK5 inhibition alone didn't impact viability or restore drug sensitivity to vemurafenib. However, in dabrafenib‐resistant cells, ERK5 inhibition reduced viability and enhanced the anti‐proliferative effect of MEK1/2 inhibition. Targeting the ERK5 pathway may represent a therapeutic opportunity in dabrafenib‐resistant melanoma.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

OximesProto-Oncogene Proteins B-rafMelanomaImidazolesVemurafenibDrug Resistance, NeoplasmMitogen-Activated Protein Kinase 7HumansCell Line, TumorIndolesSulfonamidesCell ProliferationMAP Kinase Signaling SystemCell SurvivalSkin NeoplasmsProtein Kinase InhibitorsMutation

Stichwörter der Autor:innen

BRAFERK5dabrafenibdrug‐resistancemelanomavemurafenib

Substanzen

OximesdabrafenibProto-Oncogene Proteins B-rafImidazolesVemurafenibBRAF protein, humanMitogen-Activated Protein Kinase 7IndolesSulfonamidesMAPK7 protein, human

Autor:innen und Institutionen

  • Department of Pharmacology and Therapeutics, Institute of Systems, Molecular and Integrative Biology, University of Liverpool, UK.
  • Department of Molecular and Clinical Cancer Medicine, Institute of Systems, Molecular and Integrative Biology, University of Liverpool, UK.

ORCID-Profile: Michael J Cross

Förderung

  • North West Cancer Research
  • Skin Cancer Research Fund
  • Wellcome Trust Institutional Strategic Support Fund
  • Qassim University
  • Ministry of Education, Government of Saudi Arabia

Zitieren

APA

Mondru, A. K., Wilkinson, B., Aljasir, M. A., Alrumayh, A., Greaves, G., Emmett, M., Albohairi, S., Pritchard-Jones, R., & Cross, M. J. (2024). The ERK5 pathway in BRAFV600E melanoma cells plays a role in development of acquired resistance to dabrafenib but not vemurafenib. FEBS Letters. https://doi.org/10.1002/1873-3468.14960

Vancouver

Mondru AK, Wilkinson B, Aljasir MA, Alrumayh A, Greaves G, Emmett M, et al. The ERK5 pathway in BRAFV600E melanoma cells plays a role in development of acquired resistance to dabrafenib but not vemurafenib. FEBS Letters. 2024. doi:10.1002/1873-3468.14960

BibTeX
@article{Mondru2024,
  author = {Mondru, Anil Kumar and Wilkinson, Beth and Aljasir, Mohammad A and Alrumayh, Ahmed and Greaves, Georgia and Emmett, Maxine and Albohairi, Saad and Pritchard-Jones, Rowan and Cross, Michael J},
  title = {The ERK5 pathway in BRAFV600E melanoma cells plays a role in development of acquired resistance to dabrafenib but not vemurafenib},
  journal = {FEBS Letters},
  year = {2024},
  doi = {10.1002/1873-3468.14960}
}
Kostenlos starten →